Marta Llovera

Marta Llovera

Auto-generated profile, based on publicly available information

Marta Llovera

Universitat de Lleida Lleida Spain

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1997 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MLMarta Llovera
Marta Llovera
CGCèlia Garcı́a-Martı́nez
Cèlia Garcı́a-Martı́nez
NANeus Agell
Neus Agell
FLFrancisco J. López-Soriano
Francisco J. López-Soriano
JAJosep M. Argilés
Josep M. Argilés

26 November 2008 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
KMKatharine J. M. Marler
Katharine J. M. Marler
EBElena Becker-Barroso
Elena Becker-Barroso
AMAlbert Martínez
Albert Martínez
MLMarta Llovera
Marta Llovera
CWCorinna Wentzel
Corinna Wentzel
UDUwe Drescher
Uwe Drescher
Toward understanding topographically specific branching of retinal axons in their target area, we have studied the interaction between neurotrophin receptors and members of the Eph family. TrkB and its ligand BDNF are uniformly expressed in the retina and tectum, respectively, and exert a branch-promoting activity, whereas EphAs and ephrinAs are expressed in gradients in retina and tectum and can mediate a suppression of axonal branching. We have identified a novelcisinteraction between ephrinA5 and TrkB on retinal ganglion cell axons. TrkB interacts with ephrinA5 via its second cysteine-rich domain (CC2), which is necessary and sufficient for binding to ephrinA5. Their functional interaction is twofold: ephrinA5 augments BDNF-promoted retinal axon branching in the absence of its activator EphA7–Fc, whereas EphA7–Fc application abolishes branching in a local and concentration-dependent manner. The importance of TrkB in this process is shown by the fact that overexpression of an isolated TrkB–CC2 domain interfering with the ephrinA/TrkB interaction abolishes this regulatory interplay, whereas knockdown of TrkB via RNA interference diminishes the ephrinA5-evoked increase in branching. The ephrinA/Trk interaction is neurotrophin induced and specifically augments the PI-3 kinase/Akt pathway generally known to be involved in the promotion of branching. In addition, ephrinAs/TrkB modulate axon branching and also synapse formation of hippocampal neurons. Our findings uncover molecular mechanisms of how spatially restricted axon branching can be achieved by linking globally expressed branch-promoting with differentially expressed branch-suppressing activities. In addition, our data suggest that growth factors and the EphA–ephrinA system interact in a way that affects axon branching and synapse development.

1 June 1993 in FEBS Letters
Verified
Journal Article
Closed access
CGCèlia García-Martínez
Cèlia García-Martínez
NANeus Agell
Neus Agell
MLMarta Llovera
Marta Llovera
FLFrancisco J. López-Soriano
Francisco J. López-Soriano
JAJosep M. Argilés
Josep M. Argilés

1 May 1995 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PCP Costelli
P Costelli
CGC García-Martínez
C García-Martínez
MLM Llovera
M Llovera
NCN Carbó
N Carbó
FLF J López-Soriano
F J López-Soriano
JAJ M Argilés
J M Argilés
Tissue protein hypercatabolism (TPH) is a most important feature in cancer cachexia, particularly with regard to the skeletal muscle. The rat ascites hepatoma Yoshida AH-130 is a very suitable model system for studying the mechanisms involved in the processes that lead to tissue depletion, since it induces in the host a rapid and progressive muscle waste mainly due to TPH (Tessitore, L., G. Bonelli, and F. M. Baccino. 1987. Biochem. J. 241:153-159). Detectable plasma levels of tumor necrosis factor-alpha associated with marked perturbations in the hormonal homeostasis have been shown to concur in forcing metabolism into a catabolic setting (Tessitore, L., P. Costelli, and F. M. Baccino. 1993. Br. J. Cancer. 67:15-23). The present study was directed to investigate if beta 2-adrenergic agonists, which are known to favor skeletal muscle hypertrophy, could effectively antagonize the enhanced muscle protein breakdown in this cancer cachexia model. One such agent, i.e., clenbuterol, indeed largely prevented skeletal muscle waste in AH-130-bearing rats by restoring protein degradative rates close to control values. This normalization of protein breakdown rates was achieved through a decrease of the hyperactivation of the ATP-ubiquitin-dependent proteolytic pathway, as previously demonstrated in our laboratory (Llovera, M., C. García-Martínez, N. Agell, M. Marzábal, F. J. López-Soriano, and J. M. Argilés. 1994. FEBS (Fed. Eur. Biochem. Soc.) Lett. 338:311-318). By contrast, the drug did not exert any measurable effect on various parenchymal organs, nor did it modify the plasma level of corticosterone and insulin, which were increased and decreased, respectively, in the tumor hosts. The present data give new insights into the mechanisms by which clenbuterol exerts its preventive effect on muscle protein waste and seem to warrant the implementation of experimental protocols involving the use of clenbuterol or alike drugs in the treatment of pathological states involving TPH, particularly in skeletal muscle and heart, such as in the present model of cancer cachexia.

7 February 1994 in FEBS Letters
Verified
Journal Article
Closed access
MLMarta Llovera
Marta Llovera
CGCélia García-Martínez
Célia García-Martínez
NANeus Agell
Neus Agell
MMMarc Marzábal
Marc Marzábal
FLFrancisco J. López-Soriano
Francisco J. López-Soriano
JAJosep M. Argilés
Josep M. Argilés

2 October 2014 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MCM Cornago
M Cornago
CGC Garcia-Alberich
C Garcia-Alberich
NBN Blasco-Angulo
N Blasco-Angulo
NVN Vall-Llaura
N Vall-Llaura
MNM Nager
M Nager
MLM Llovera
M Llovera
Glioblastoma multiforme is resistant to conventional anti-tumoral treatments due to its infiltrative nature and capability of relapse; therefore, research efforts focus on characterizing gliomagenesis and identifying molecular targets useful on therapy. New therapeutic strategies are being tested in patients, such as Histone deacetylase inhibitors (HDACi) either alone or in combination with other therapies. Here two HDACi included in clinical trials have been tested, suberanilohydroxamic acid (SAHA) and valproic acid (VPA), to characterize their effects on glioma cell growth in vitro and to determine the molecular changes that promote cancer cell death. We found that both HDACi reduce glioma cell viability, proliferation and clonogenicity. They have multiple effects, such as inducing the production of reactive oxygen species (ROS) and activating the mitochondrial apoptotic pathway, nevertheless cell death is not prevented by the pan-caspase inhibitor Q-VD-OPh. Importantly, we found that HDACi alter cell cycle progression by decreasing the expression of G2 checkpoint kinases Wee1 and checkpoint kinase 1 (Chk1). In addition, HDACi reduce the expression of proteins involved in DNA repair (Rad51), mitotic spindle formation (TPX2) and chromosome segregation (Survivin) in glioma cells and in human glioblastoma multiforme primary cultures. Therefore, HDACi treatment causes glioma cell entry into mitosis before DNA damage could be repaired and to the formation of an aberrant mitotic spindle that results in glioma cell death through mitotic catastrophe-induced apoptosis.